missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Mouse IL-3 Recombinant Protein, PeproTech®
Click to view available options
Quantity:
1 mg
10 μg
100 μg
2 μg
250 μg
50 μg
500 μg
Unit Size:
100µg
10µg
1mg
250µg
2µg
500µg
50µg
Description
Recombinant Murine IL-3 is a 15.1 kDa globular protein containing 135 amino acid residues. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Interleukin 3 (IL-3), also called Mast Cell Growth Factor (MCGF), Multi-Colony Stimulating Factor (multi-CSF), or Eosinophil-CSF (E-CSF), is produced by activated T cells, mast cells and eosinophils. IL-3 is a hematopoietic growth factor that stimulates colony formation of erythroid, megakaryocyte, neutrophil, eosinophil, basophil, mast cell and monocytic lineages. Most of these functions are enhanced or dependent on co-stimulation with other cytokines. Human and mouse IL-3 share only 29% sequence identity at the amino acid level. The bioactivity of IL-3 is highly species specific. For example, human IL-3 has no activity on mouse cells. IL-3 is a potent growth promoting cytokine. IL-3 is capable of supporting the proliferation of a broad range of hematopoietic cell types, and is involved in a variety of cell activities such as cell growth, differentiation and apoptosis. IL-3 has been shown to also possess neurotrophic activity, and it may be associated with neurologic disorders.
Specifications
Specifications
| Accession Number | P01586 |
| For Use With (Application) | ELISA, Functional Assay, Western Blot |
| Formulation | protein with no preservative |
| Gene ID (Entrez) | 16187 |
| Molecular Weight (g/mol) | 15.1 kDa |
| Name | Mouse IL-3 |
| Quantity | 10 μg |
| Source | E. coli |
| Regulatory Status | RUO |
| Endotoxin Concentration | <1 EU/ μg |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction